4.7 Article

Discovery of the First Druggable GPR52 Antagonist to Treat Huntington's Disease

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Chemistry, Medicinal

GPR52 Antagonist Reduces Huntingtin Levels and Ameliorates Huntington's Disease-Related Phenotypes

Congcong Wang et al.

Summary: The study confirms GPR52 inhibition as a promising strategy for HD therapy, with the discovery of a highly potent and specific GPR52 antagonist Comp43 that reduces mHTT levels and promotes survival of mouse primary striatal neurons. Comp43 not only reduces inHTT levels, but also rescues HD-related phenotypes in HdhQ140 mice, suggesting it as a lead compound for further investigation.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

Article Multidisciplinary Sciences

Structural basis of ligand recognition and self-activation of orphan GPR52

Xi Lin et al.

NATURE (2020)

Review Pharmacology & Pharmacy

Gene therapy for neurodegenerative disorders: advances, insights and prospects

Wei Chen et al.

ACTA PHARMACEUTICA SINICA B (2020)